May 13, 2021 / 03:00PM GMT
Stephen Rogers Sloan - BofA Securities, Research Division - Research Analyst
All right. Thank you for joining us. It's my pleasure to be here with Bryan Stuart, President and CEO of Fulcrum. So Bryan, great to have you, and please go ahead.
Bryan E. Stuart - Fulcrum Therapeutics, Inc. - President, CEO & Director
Wonderful. And thank you for the opportunity, and thank everybody for joining us here today.
So today, we'll be making some forward-looking statements about the company, and you'll see here on Slide 3. So at Fulcrum, we're really focused on regulating gene expression to treat the root cause of genetically defined rare disease. And we've built our organization and our approach, really taking advantage of some of the very meaningful advances that have taken place in terms of disease understanding over the last number of decades. So there's been a great advancement in terms of understanding gene regulation and understanding the genetic root causes of hundreds or thousands of rare diseases. And we've built up at Fulcrum, a product engine, as you
Fulcrum Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot